The aim of the study was to define clinical utility of serum biomarkers: VEGF, MMP-2, MMP-9, TIMP-1, and YKL-40 in patients with skin melanoma at locoregional stage. This evidence concerns the gene TIMP1 and cutaneous melanoma.